Responses to COVID-19 from Dow Life Sciences

Dow Life Sciences is a strategic market segment in Dow. The goal of this market segment is to deliver high quality product and technical solutions to Human Health and Human Comfort. There are 5 sub-platforms that we are participating in: API and Manufacturing, Topical Drugs, Oral Drugs, Biopharmaceutical, and medical devices. Dow products sold in this area include Carbowax Sentry PEGs, Isopropanol, defoamers etc. Under this challenging COVID-19 scenario, our Life Sciences global team, quickly responded by identifying unmet needs from the market and customers. Due to the high demand of isopropanol (IPA), the first response was to address the supply issue. This resulted in a capacity expansion of IPA. Meanwhile, we also coordinated the IPA supply among various pharmaceutical customers and continued supporting our strategic customers to launch drug products. In addition to IPA, our global team also captured opportunities related to other Dow products such as amines, chelants, and PEGs to support our global pharma customers in formulated hand sanitizers. Meanwhile, some disruptive opportunities were also identified and investigated due to a great effort and collaboration across Dow multiple functions.